REFERENCES:

Table 1. The frequencies of non-vascular pulmonary manifestations in patients with Takayasu arteritis

<table>
<thead>
<tr>
<th>n (%) All Patients</th>
<th>Patients with PAH</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>n=197</td>
<td>n=22</td>
</tr>
<tr>
<td>Symptoms</td>
<td>24 (12.2)</td>
<td>3 (13.6)</td>
</tr>
<tr>
<td>Cough/Dyspnea</td>
<td>4 (2)</td>
<td>3 (13.6)</td>
</tr>
<tr>
<td>Hemoptysis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pulmonary involvement in CT</td>
<td>10 (5.1)</td>
<td>5 (22.7)</td>
</tr>
<tr>
<td>Pulmonary infiltrates</td>
<td>4 (2)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Nodules/cavities</td>
<td>1 (0.5)</td>
<td>1 (4.5)</td>
</tr>
<tr>
<td>Pulmonary hemorrhage</td>
<td>5 (2.5)</td>
<td>2 (9.1)</td>
</tr>
<tr>
<td>Pleural effusion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(PAH: pulmonary arterial hypertension, CT: computed tomography)

Scleroderma, myositis and related syndromes

FR0300 IMPACT OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS IN A COMPLETE, NATIONWIDE COHORT
Anna-Maria Hoffmann-Vold1, Håvard Fretheim1, Anna-Kristine H. Halse2, Trond M. Aaløkken1, Øyvind Midtvedt1, Øyvind Molberg1.

Background: Interstitial lung disease (ILD) represents a clinical challenge in systemic sclerosis (SSc) and associates with high mortality. The presence of severe lung fibrosis is a strong predictor for early mortality. There is substantial progress in SSc-ILD research, but precise, population-based data on cumulative incidence, range of severity and predictive value of clinical risk factors are lacking. Such data are vital for clinical decision making, and highly warranted as background information for appropriate development of screening and management strategies for SSc-ILD.

Objectives: To assess cumulative incidence of ILD, range of ILD severity and mortality risk predicted by baseline pulmonary function tests (PFT) and ILD extent by CT in a complete, nationwide SSc cohort.

Methods: The Norwegian SSc cohort study (Nor-SSc) includes all the 630 incident and 185 prevalent SSc patients from 2000-2012 meeting SSc classification criteria. A baseline PFT was recorded in 703 (86%) patients, and 650 (80%) had high resolution computed tomography (HRCT) images available for analyses. Extent of fibrosis was scored on 10 sections from every HRCT and expressed as percentage of total lung volumes. For the survival and mortality analyses, all Nor-SSc patients diagnosed from 2000-2012 (the 630 incident cases) were included and compared with 15 age- and gender matched controls per patient drawn from the national population registry. Vital status was available for all patients and controls at study end (January 2018). Descriptive statistics and standardized mortality rates (SMR) were estimated.

Results: Of the 815 patients in the total Nor-SSc cohort, 682 (84%) were female and 629 (77%) had limited cutaneous SSc. Mean age at SSc diagnosis was 53 yrs, with mean time from SSc onset to diagnosis of 3.8 yrs. We observed ILD on HRCT in 324/650 patients (50%), and the majority of these had >5% lung fibrosis (Figure 1A). Mean FVC at baseline was 94% of expected value, and nearly half of the patients (42%) had an FVC<100% (Figure 1B). Proportionate distribution of FVC values in patients with no lung fibrosis, <10% lung fibrosis of total lung volume and >10% lung fibrosis is shown in Figure 1C. During the mean 8.6 yrs observation period of this study, 148 of the 630 incident SSc patients died, corresponding to an overall SMR of 2.4. Separate analyses of the 650 patients with baseline HRCT data showed that the SMR correlated with presence and extent of lung fibrosis, from SMR 2.2 in patients with no fibrosis to SMR 8 in patients with >25% lung fibrosis (Figure 1D). Correspondingly, we found that the SMR changed across patient groups stratified by baseline FVC%, with increased mortality evident already in the FVC 90-100% group (Figure 1E).

Conclusion: The results from this population based SSc cohort study provide new, unbiased data regarding the impact of ILD. Our results indicate a dose-response relationship between lung fibrosis extent and SMR; and between FVC% and SMR. Importantly, this relationship was evident even in groups with limited lung fibrosis and groups with normal range FVC%, strongly suggesting that all SSc patients should be screened with PFT and HRCT at baseline, to diagnose ILD early and tailor further management.

Disclosure of Interests: Ayten Yazici: None declared, Ayse Cefle: None declared, Sema Kaymaz Tahra: None declared, Nilüfer Alpay Kan: None declared, Mete Kara: None declared, Önay Gerçik: None declared, Anne Salberg: None declared, Torhild Garen: None declared, May Brit Lund: None declared, Trond M. Aaløkken: None declared, Håvard Fretheim: None declared, Øyvind Molberg: None declared.


FR0301 GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) TREATED WITH NINTEDANIB: DATA FROM THE SENSCIS TRIAL
Toby Maher1, Kristin Highland2, Martina Gahlemann3, Arata Azuma4, Mannaig Girard9, Margarida Alves10, Emmanuelle Clerisme-Beaty10, Veronika Kohlbrenner11, Masataka Kuwana12, Oliver Distler13.

Background: In patients with idiopathic pulmonary fibrosis (IPF), nintedanib has a manageable adverse event (AE) profile characterised predominantly by gastrointestinal (GI) events. The efficacy and safety of nintedanib was evaluated in the 617 patients participating in the SENSCIS trial, a randomised controlled trial comparing nintedanib with placebo in patients with SSC-ILD.

Methods: Nineteen AE were systematically collected in each patient over 12 months while on treatment and followed-up for 24 months. The combined incidence of the most common GI AEs (constipation, diarrhoea, nausea and vomiting) was assessed and all AEs were classified using MedDRA version 22.0.

Results: In the SENSCIS trial 617 patients were evaluable for efficacy and 537 for safety at 24 months. The most common GI AEs were constipation (n=205, 33.8%), diarrhoea (n=121, 22.7%) and nausea (n=118, 21.6%). The median number of days with AEs was 22 for constipation, 19 for diarrhoea and 15 for nausea. The number of patients experiencing AEs was low for all AE. The total percentage of patients with at least 1 AE was 84.4% for constipation, 53.0% for diarrhoea and 51.3% for nausea.

Discussion of AE: The 6.5% and 3.3% of patients in the SENSCIS trial who discontinued the study due to an AE were due to diarrhoea and constipation respectively. There were no deaths due to AEs.

Conclusion: Nintedanib is well tolerated and not associated with excess mortality in patients with SSC-ILD. The median number of days with AEs was low for all AE.

Disclosure of Interests: Anna-Maria Hoffmann-Vold Grant/research support from: Received research funding or other remuneration from Boehringer Ingeheim, GSK, and Actelion, Consultant for: Received consulting fees or other remuneration from Boehringer Ingeheim, GSK, and Actelion, Investigator for: Received travel grants from Boehringer Ingeheim and Actelion, Research grant/other support: Boehringer Ingeheim and Actelion, Speakers bureau: Actelion and Boehringer Ingeheim, Håvard Fretheim Consultant for: Received consulting fees or other remuneration from GSK, and Actelion, Anna-Kristine H. Halse: None declared, Marit Seip: None declared, Helle Bitter: None declared, Marianne Wallenius: None declared, Anne Salberg: None declared, Torhild Garen: None declared, May Brit Lund: None declared, Trond M. Aaløkken: None declared, Øyvind Midtvedt: None declared, Øyvind Molberg: None declared.

Results: A total of 576 patients (288 per group) received 1 dose of nintedanib or placebo. Over 52 weeks, 13.9% and 7.3% of patients treated with nintedanib and placebo discontinued study drug due to AE. The most frequent AEs in patients treated with nintedanib were diarrhoea (75.7% vs 31.6%), nausea (31.6% vs 13.5%) and vomiting (24.7% vs 10.4%). Serious diarrhoea AEs were reported in 2 patients (0.7%) in each group, and serious vomiting AEs were reported in 2 patients (0.7%) in the placebo group and none in the nintedanib group. Of the 216 nintedanib-treated patients who experienced a diarrhoea AE, most experienced events that were at worst of mild (49.5%) or moderate (40.5%) intensity, most (70.2%) experienced 1 or 2 events, and the duration of diarrhoea AEs was <9 days for 50% of the events over the reported over 52 weeks. Among nintedanib-treated patients who experienced diarrhoea AE, 26.1% had a permanent dose reduction and 9.2% discontinued study drug due to the AE. Among the 91 patients in the placebo group who experienced diarrhoea AE, the duration of diarrhoea AEs was <3 days for 50% of the events reported over 52 weeks, 2.2% had a permanent dose reduction and 1.1% discontinued study drug due to the AE.

Conclusion: In patients with SSc-ILD, the gastrointestinal AEs associated with nintedanib were manageable for most patients and consistent with its known safety and tolerability profile in patients with IPF.

Disclosure of Interests: Toby Maher Grant/research support from: Received funds from BI advisory board participation and conference travel. Received research funding and/or consulting fees or other remuneration from: GSK, UCB, AstraZeneca, Roche, Bayer, Biogen Idec, Cipla, Prometic, and Sanumed. Toby Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB. Consultant for: Toby Maher has received consultancy or speakers fees from Apellis, AstraZeneca, Bayer, Biogen Idec, Boehringer Ingelheim, Galapagos, GlaxoSmithKline R&D, Indalo, Pliant, ProMetic, Roche, Sanumed and UCB; and has received consultancy fees from Galeotti, Kristin Highland Grant/research support from: Kristin Highland is a site PI for the SENSCIS trial (Dr Highland’s institution has the contract for the study) which is funded by Boehringer Ingelheim, Consultant for: Kristin Highland is a paid consultant for Boehringer Ingelheim through her role sitting on the steering committee., Speakers bureau: Kristin Highland is on the speakers’ bureau for Boehringer Ingelheim, Martina Gahiemann Employee of: Employee of Boehringer Ingelheim, Arata Azuma Consultant for: Arata Azuma received personal fees from Roche and BMS. Mayes Grant/research support from: Arayh Fischer has received a grant from Boehringer Ingelheim (Consultant/steering committee member/principal investigator on clinical trials), Genentech-Roche (Consultant/steering committee member/principal investigator on clinical trials), Pfizer (Consultant) and Genentech (Consultant), Maureen Mayes Grant/research support from: Maureen Mayes is a clinical trial investigator for Boehringer-Ingelheim; Galapagos, Reata, Sanofi, Merck Serono, Consultant for: Maureen Mayes is a member of scientific advisory boards for Galapagos NV (Pharma), Boehringer-Ingelheim, Mitsubishi Tanabe, Astellas; Grant Review Board for Actelion., Speakers bureau: Maureen Mayes received personal fees for being a conference speaker on the use of autoantibodies in connective tissue diseases for Medtelligence, Gameh Negash Raghu Grant/research support from: Gameh Negash is the principal investigator for IPF net studies and is a steering committee member for the IPF net studies for the NHLI. Consultant for the British Lung Foundation is a consultant for Boehringer Ingelheim, Bellopheron, Biogen, BMS, Fibrogilen, Gilead, Nitto, Revistan, Promodior, Sanofi, Veracyte and Roche-Genentech; and a consultant and chair of the DSMB for Avalyn., Wiebke Sauter Employee of: Wiebke Sauter is an employee of Boehringer Ingelheim, Mannna Girard Employee of: Mannna Girard is an employee of Boehringer Ingelheim, Margarida Alves Employee of: employee of Boehringer Ingelheim, Emmanuelle Clerisme-Beaty Employee of: Emmanuelle Clerisme-Beaty is an employee of Boehringer Ingelheim, Veronika Kompatsiaris Employee of: Employee of Boehringer Ingelheim, Masataka Kuwana Grant/research support from: Actelion, Consultant for: Chugai, Reata, GlaxoSmithKline, Bayer, Boehringer-Ingelheim, Coropus, CSL-Berling, Mochida, Speakers bureau: Actelion, Pfizer, Bayer, Nippon Shinyaku, Chugai, Olver Diستر Grant/research support from: Prof. Distler has had consultancy relationship with the last 3 years with Actelion, AnaMar, Bayer, Boehringer Ingelheim, ChemomAb, espreRare foundation, Genentech/Roche, GSK, Inventiva, Italfarmaco, iQvia, Lilly, medac, MedImmune, Mitsubishi Tanabe Pharma, Pharmacodynamics, Novartis, Pfizer, Sanofi, Sero-dapharm and UCB in the area of potential treatments of scleroderma and its complications. In addition, he had has/had consultancy relationship within the last 3 years with A. Menarini, Amgen, Abbvie, GSK, Mepha, MSD, Pfizer and UCB in the field of arthritides and related disorders DOI: 10.1136/annrheumdis-2019-eular.3995

FRI0302

SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY

Glorioso Campochiaro1, Giacomo De Luca2, Maria Grazia Lazzaaroni2, Silvia Lorusso2, Laura Boselli2, Davide Canta3, Carlo Selmi3, Elisa Gremsa3, Paolo Airo2, Marco Mattucci-Cerinic2, Lorenzo Dagna1. 1IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases, Milan, Italy; 2Spedali Civili and University of Brescia, Rheumatology and Clinical Immunology, Brescia, Italy; 3Fondazione Poli Clinico Universitario A. Gemelli, Division of Rheumatology, Rome, Italy; 4Humanitas Research Hospital, Division of Rheumatology and Clinical Immunology, Milan, Italy, 5University of Florence, Division of Rheumatology AOUC, Florence, Italy

Background: recent data support the use of rituximab (RTX) in Systemic Sclerosis (SSc). RTX biosimilar (RTX-B) offers a more affordable option but its efficacy and safety have not yet been evaluated.

Objectives: To assess the safety and efficacy of RTX-B in SSc.

Methods: Data about SSc patients treated with RTX-B (1gr repeated after 2 weeks) and with a follow-up >6 months were retrospectively collected from 5 Italian centres. Both SSc patients naïve to RTX (RTX-Bn) or already treated with >1 course of RTX originator (RTX-O) and switched to RTX-B (RTX-Bs) were considered. A comprehensive assessment of disease features and organ involvement was available at baseline and at final follow up for all patients. Non parametric tests were used.

Results: Data of 21 SSc patients (20 female, mean age 50.5±11.8 years) were collected; mean disease duration at RTX-B therapy was 6.4±4.8 yrs. Eleven patients (52%) had diffuse cutaneous SSc (dcSSc), 12 (57%) were anti-topoisomerase1+, 5 anti-RNA-polymerase1+ and 4 anti-centrome1+. Twelve patients (57%) were RTX-Bn and 9 RTX-Bs (43%). In RTX-Bn patients, the median number of previous RTX-O courses was 3 (range 1–8). RTX was decided because of skin progression in 11 (52%), interstitial lung disease (ILD) worsening in 9 (43%), arthritis in 6 (29%), myositis in 1 patient each. All patients had been previously treated with immunosuppressants: mycophenolate mofetil/MMF (14/67%), methotrexate (MTX) (7/33%), cyclophosphamide (6/29%), azathioprine (4/19%), tocilizumab and etanercept (5/5%) patient each. At RTX-B introduction, 14 (67%) patients were on concomitant immunosuppressant (10/48%) MMF and 4 (19%) MTX; 15 patients(71%) were also on steroids (mean dose 3.1 ±2.1 mg/day). At 6 months after RTX-B treatment, a significant reduction of the modified Rodnan skin score(mRSS), DAS28 and erythrocyte sedimentation rate(ESR) was observed in the entire cohort (p<0.001, p<0.028, p<0.003, respectively); mRSS was significantly reduced also in RTX-Bs (p=0.011) and RTX-Bs patients (p=0.046) (Table 1). No significant changes were observed for lung function tests. Only 1 RTX-Bs patient experienced a transient neutropenia 3 months after the 2nd RTX-B infusion whilst also on MTX.

Conclusion: in agreement with previous data published on RTX-O, also RTX-B seem efficient in improving skin and joint involvement and in stabilizing lung function, either in RTX-Bn and in RTX-Bs SSc patients.

REFERENCE:

832 Friday, 14 June 2019

Scientific Abstracts